Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meet EU Safety Feature Deadline Or Face Penalties, Firms Warned

Executive Summary

Pharma firms, distributors and pharmacies have been warned that they need to take action to ensure they are ready for the implementation of Europe's product verification system in February 2019. Brexit, though, has cast uncertainty over the extent of the UK's participation in the new system.

You may also be interested in...



MHRA Explains Its Approach To New 'Safety Features' In 2019

The MHRA has set out its position on those aspects of the new “safety feature” rules for prescription drugs where member states have flexibility to choose their options, such as the information to be included in the “unique identifier” and the conditions for “checking out” medicines from the verification system. The European Medicines Verification System is being introduced as part of the EU Falsified Medicines Directive.

Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline

Concerns that the US pharmaceutical industry will not have the necessary serialization systems in place to fully comply with DSCSA product package serialization requirement appear to be bearing fruit, according to a recent survey.

Higher Costs, Higher Fees, Higher Drug Prices: The UK No-Deal Brexit Bonus

A freestanding UK Medicines and Healthcare products Regulatory Agency with a dedicated authorization route for new drugs OKd by the European Medicines Agency and national incentives for pediatric and orphan drug development are just some of the likely outcomes of a no-deal Brexit as described in a consultation document just released by the government. In many cases companies will end up paying again for services they currently receive from the EMA, and, the government says, they may pass these extra costs onto the national health service in the form of higher prices.

Related Content

Topics

UsernamePublicRestriction

Register

PS124111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel